{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:47:43Z","timestamp":1790819263314,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001632","name":"Ulster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.reprotox.2021.01.006","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T19:40:41Z","timestamp":1610653241000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7268-6820","authenticated-orcid":false,"given":"Aminkeng Zawuo","family":"Leke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Dolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-3637","authenticated-orcid":false,"given":"Maria","family":"Loane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Casson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Nelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9085-6747","authenticated-orcid":false,"given":"Ingeborg","family":"Bari\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0430-2594","authenticated-orcid":false,"given":"Ester","family":"Garne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Neville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3929-3619","authenticated-orcid":false,"given":"Jorieke E.H.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Klungs\u00f8yr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-5892","authenticated-orcid":false,"given":"Anna","family":"Materna-Kiryluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Latos","family":"Bielenska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4858-6456","authenticated-orcid":false,"given":"Clara Cavero","family":"Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-918X","authenticated-orcid":false,"given":"Marie-Claude","family":"Addor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.reprotox.2021.01.006_bib0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3949\/ccjm.80a.13077","article-title":"Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused?","volume":"80","author":"Giudicessi","year":"2013","journal-title":"Cleve. Clin. J. Med."},{"issue":"6","key":"10.1016\/j.reprotox.2021.01.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00438-18","article-title":"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides","volume":"62","author":"Gorelik","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.reprotox.2021.01.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008074","article-title":"Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities","volume":"7","author":"Polgreen","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"15","key":"10.1016\/j.reprotox.2021.01.006_bib0020","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1503\/cmaj.140572","article-title":"The cardiovascular safety of azithromycin","volume":"186","author":"Juurlink","year":"2014","journal-title":"Can. Med. Assoc. J."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-7-255","article-title":"Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy","volume":"7","author":"Chico","year":"2008","journal-title":"Malar. J."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0030","series-title":"WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy Using Sulfadoxine-pyrimethamine (IPTp-SP) [Internet]","year":"2014"},{"issue":"6","key":"10.1016\/j.reprotox.2021.01.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157045","article-title":"Efficacy and safety of azithromycin-chloroquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of plasmodium falciparum malaria infection in pregnant women in Africa: an open-label, randomized trial","volume":"11","author":"Kimani","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.reprotox.2021.01.006_bib0040","series-title":"Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology [Internet]","author":"Simpson","year":"2020"},{"issue":"3","key":"10.1016\/j.reprotox.2021.01.006_bib0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0890-6238(03)00012-1","article-title":"Maternal drug use in early pregnancy and infant cardiovascular defect","volume":"17","author":"Kallen","year":"2003","journal-title":"Reprod. Toxicol."},{"issue":"2","key":"10.1016\/j.reprotox.2021.01.006_bib0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.reprotox.2005.01.010","article-title":"Is erythromycin therapy teratogenic in humans?","volume":"20","author":"K\u00e4ll\u00e9n","year":"2005","journal-title":"Reprod. Toxicol."},{"issue":"3","key":"10.1016\/j.reprotox.2021.01.006_bib0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-013-1624-3","article-title":"Fetal safety of erythromycin. An update of Swedish data","volume":"70","author":"K\u00e4ll\u00e9n","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmj.m331","article-title":"Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study","author":"Fan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.reprotox.2021.01.006_bib0065","first-page":"484","article-title":"Pregnancy outcome after gestational exposure to the new macrolides: a prospective controlled cohort study","volume":"20","author":"Tellem","year":"2005","journal-title":"Reprod. Toxicol."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejogrb.2008.07.008","article-title":"Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study","volume":"141","author":"Bar-Oz","year":"2008","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-3016.2008.00978.x","article-title":"Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations","volume":"23","author":"Cooper","year":"2009","journal-title":"Paediatr. Perinat. Epidemiol."},{"issue":"11","key":"10.1016\/j.reprotox.2021.01.006_bib0080","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archpediatrics.2009.188","article-title":"Antibacterial medication use during pregnancy and risk of birth defects: national Birth Defects Prevention Study","volume":"163","author":"Crider","year":"2009","journal-title":"Arch. Pediatr. Adolesc. Med."},{"issue":"30","key":"10.1016\/j.reprotox.2021.01.006_bib0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.reprotox.2010.05.034","article-title":"Safety of macrolides during pregnancy\u2014With special focus on erythromycin and congenital heart malformations","volume":"2","author":"Nordeng","year":"2010","journal-title":"Reprod. Toxicol."},{"issue":"6","key":"10.1016\/j.reprotox.2021.01.006_bib0090","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04286.x","article-title":"Pregnancy outcome after gestational exposure to erythromycin\u2013a population\u2010based register study from Norway","volume":"74","author":"Rom\u00f8ren","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.reprotox.2021.01.006_bib0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2165\/11630920-000000000-00000","article-title":"The outcomes of pregnancy in women exposed to the new macrolides in the first trimester","volume":"35","author":"Bar-Oz","year":"2012","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.reprotox.2021.01.006_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2012.12.023","article-title":"Safety of macrolides during pregnancy","volume":"208","author":"Lin","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/364526","article-title":"Trimethoprim use prior to pregnancy and the risk of congenital malformation: a register-based nationwide cohort study","volume":"2013","author":"Andersen","year":"2013","journal-title":"Obstet. Gynecol. Int."},{"issue":"7","key":"10.1016\/j.reprotox.2021.01.006_bib0110","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1128\/AAC.01691-12","article-title":"Fetal safety of macrolides","volume":"57","author":"Dinur","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.reprotox.2021.01.006_bib0115","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/pds.3900","article-title":"Use of macrolides during pregnancy and the risk of birth defects: a population\u2010based study","volume":"24","author":"B\u00e9rard","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"11","key":"10.1016\/j.reprotox.2021.01.006_bib0120","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/bcp.13364","article-title":"Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study","volume":"83","author":"Muanda","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.reprotox.2021.01.006_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.06.050","article-title":"In utero exposure to antibiotics and risk of congenital malformations: a population-based study","volume":"221","author":"Damkier","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.reprotox.2021.01.006_bib0130","first-page":"234","article-title":"A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin","volume":"79","author":"Czeizel","year":"2000","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"6","key":"10.1016\/j.reprotox.2021.01.006_bib0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0890-6238(99)00046-5","article-title":"A population-based case-control teratologic study of oral erythromycin treatment during pregnancy","volume":"13","author":"Czeizel","year":"1999","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0140","article-title":"Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis","volume":"12","author":"Mallah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0145","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s10654-015-0099-1","article-title":"Response to: case\u2013control studies require appropriate population controls: an example of error in the SSRI birth defect literature","author":"Dolk","year":"2015","journal-title":"Eur. J. Epidemiol."},{"issue":"23","key":"10.1016\/j.reprotox.2021.01.006_bib0150","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations","volume":"362","author":"Jentink","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.reprotox.2021.01.006_bib0155","first-page":"S46","article-title":"EUROmediCAT: European surveillance of safety of medication use in pregnancy","volume":"20","author":"de Jong-van den Berg","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0160","series-title":"EUROCAT Guide 1.4 Reference Documents [Internet]","year":"2018"},{"issue":"S1","key":"10.1016\/j.reprotox.2021.01.006_bib0165","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1002\/bdra.20775","article-title":"Paper 6: EUROCAT member registries: organization and activities","volume":"91","author":"Greenlees","year":"2011","journal-title":"Birth Defects Res. Part A Clin. Mol. Teratol."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0170","series-title":"EUROCAT Special Report: Sources of Information on Medication Use in Pregnancy","author":"Bakker","year":"2014"},{"key":"10.1016\/j.reprotox.2021.01.006_bib0175","series-title":"Maternal Use and Safety of Anti-Infectives in Pregnancy, with Special Reference to Cameroon Doctoral Dissertation","first-page":"159","author":"Leke","year":"2017"},{"key":"10.1016\/j.reprotox.2021.01.006_bib0180","series-title":"Modern Epidemiology","year":"2008"},{"issue":"5","key":"10.1016\/j.reprotox.2021.01.006_bib0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/(SICI)1096-9926(200005)61:5<325::AID-TERA1>3.0.CO;2-M","article-title":"What kind of controls to use in case control studies of malformed infants: recall bias versus \u201cteratogen nonspecificity\u201d bias","volume":"61","author":"Hook","year":"2000","journal-title":"Teratology"},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0190","first-page":"116","article-title":"Towards a drug concentration effect relationship for QT prolongation and torsades de pointes","volume":"5","author":"Webster","year":"2002","journal-title":"Curr. Opin. Drug Discov. Dev."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/cvr\/cvs296","article-title":"Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism","volume":"97","author":"Danielsson","year":"2013","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.RES.78.1.15","article-title":"Developmental changes in ionic channel activity in the embryonic murine heart","volume":"78","author":"Davies","year":"1996","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.RES.79.1.79","article-title":"Developmental changes in the delayed rectifier K+ channels in mouse heart","volume":"79","author":"Wang","year":"1996","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.reprotox.2021.01.006_bib0210","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/cvr\/28.3.337","article-title":"Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant","volume":"28","author":"Abrahamsson","year":"1994","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ar.1091510107","article-title":"Hemodynamic factors in the development of the chick embryo heart","volume":"151","author":"Jaffee","year":"1965","journal-title":"Anat. Rec."},{"issue":"2","key":"10.1016\/j.reprotox.2021.01.006_bib0220","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/mob.2002.119718","article-title":"Erythromycin use during pregnancy in relation to pyloric stenosis","volume":"186","author":"Louik","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0225","doi-asserted-by":"crossref","first-page":"g1908","DOI":"10.1136\/bmj.g1908","article-title":"Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study","volume":"348","author":"Lund","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.reprotox.2021.01.006_bib0230","first-page":"101","article-title":"Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis","volume":"100","author":"Cooper","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0235","series-title":"BNF 77 (British National Formulary) March 2019","author":"Joint Formulary Committee","year":"2019"},{"key":"10.1016\/j.reprotox.2021.01.006_bib0240","series-title":"EUROCAT Website Data on Prenatal Detection Rates of Congenital Anomalies","author":"Garne","year":"2010"},{"issue":"10","key":"10.1016\/j.reprotox.2021.01.006_bib0245","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1093\/jac\/dkq307","article-title":"Oral antibiotic prescribing during pregnancy in primary care: UK population-based study","volume":"65","author":"Petersen","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.reprotox.2021.01.006_bib0250","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40264-015-0321-9","article-title":"Improving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT study","volume":"38","author":"de Jonge","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.reprotox.2021.01.006_bib0255","article-title":"Analysis goals, error\u2010cost sensitivity, and analysis hacking: essential considerations in hypothesis testing and multiple comparisons","author":"Greenland","year":"2020","journal-title":"Paediatr Perinatal Epidemiol."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623821000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623821000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:54:52Z","timestamp":1760190892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623821000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":51,"alternative-id":["S0890623821000204"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2021.01.006","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2021.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}